Merck : MRK

All Merck Articles

1085 Articles

Chris Lange | Jul 26, 2020 at 6:33 AM EDT

Apple, Boeing, Exxon, McDonald’s, Visa and More Dow Earnings This Week

24/7 Wall St. has put together a preview of those Dow companies scheduled to report their quarterly results this week,…

Chris Lange | May 26, 2020 at 10:37 AM EDT

Meet Merck’s Newest Collaborations in the Fight Against COVID-19

Merck shares jumped on Tuesday after the company announced that it has made deals to develop drugs in the fight…

Chris Lange | Apr 28, 2020 at 1:17 PM EDT

Why Pfizer and Merck Earnings Are Slowing the Dow

Merck and Pfizer reported their most recent quarterly results before the opening bell Tuesday. Although markets appear to be recovering,…

Chris Lange | Apr 27, 2020 at 12:13 PM EDT

What to Watch When Merck and Pfizer Report Tuesday Morning

Pharmaceutical giants Merck and Pfizer are expected to report their most recent quarterly results before the opening bell Tuesday.

Chris Lange | Apr 27, 2020 at 9:37 AM EDT

Big Pharma Short Sellers Can’t Make Up Their Minds

The April 15 short interest data have been compared with the previous figures, and short interest moves in these selected…

Chris Lange | Apr 26, 2020 at 7:20 AM EDT

Apple, Exxon, Microsoft, Pfizer and More Dow Earnings Coming This Week

Over one-third of the Dow Jones industrial average components are scheduled to report their latest quarterly reports this week. Here's…

Chris Lange | Apr 13, 2020 at 9:58 AM EDT

Big Pharma Short Sellers Focus on a Couple of Favorites

The March 31 short interest data have been compared with the previous figures, and short interest moves in these selected…

Jon C. Ogg | Mar 16, 2020 at 1:32 PM EDT

9 Dividends That Should Absolutely Not Be Killed During the Coronavirus Recession

24/7 Wall St. wanted to see which companies have the best chance at not having to lower their dividends at…

Chris Lange | Mar 11, 2020 at 9:44 AM EDT

Short Sellers Run for Cover From Big Pharma Stocks

The February 28 short interest data have been compared with the previous figures, and short interest in these top pharmaceutical…

Chris Lange | Feb 27, 2020 at 8:45 AM EST

Big Pharma Scares Off Short Sellers

The February 14 short interest data have been compared with the previous figures, and short interest in most of these…

Jon C. Ogg | Feb 20, 2020 at 7:35 AM EST

15 Top ESG Stocks That Look Undervalued for 2020

With billions of dollars flowing in, it has become impossible to ignore the ESG trend. These 15 top ESG stocks…

Chris Lange | Feb 12, 2020 at 9:50 AM EST

Big Pharma Sees a Rising Tide in Short Interest

The January 31 short interest data have been compared with the previous figures, and short interest in most of these…

Jon C. Ogg | Feb 6, 2020 at 8:45 AM EST

Top Analyst Upgrades and Downgrades: AbbVie, Biogen, Boeing, Etsy, Gilead, GoPro, Micron, Newmont, Peloton, Pfizer, Valero, Zynga and More

Thursday's top analyst upgrades, downgrades and initiations included AbbVie, Biogen, Boeing, Etsy, Gilead Sciences, GoPro, Micron Technology, Newmont, Peloton Interactive,…

Jon C. Ogg | Feb 5, 2020 at 1:20 PM EST

Merck’s Spin-Off May Create Operational Risks for the Year Ahead

Merck finds itself in a position of being an acquirer of sorts at the same time it wants to spin…

Chris Lange | Feb 5, 2020 at 9:55 AM EST

Is Merck Stuck in the Slow Lane?

Merck reported fourth-quarter financial results before the markets opened on Wednesday that were essentially in line with expectations, yet shares…

1 … 12 13 14 15 16 … 73

Merck : MRK

All Merck Articles

Apple, Boeing, Exxon, McDonald’s, Visa and More Dow Earnings This Week

Meet Merck’s Newest Collaborations in the Fight Against COVID-19

Why Pfizer and Merck Earnings Are Slowing the Dow

What to Watch When Merck and Pfizer Report Tuesday Morning

Big Pharma Short Sellers Can’t Make Up Their Minds

Apple, Exxon, Microsoft, Pfizer and More Dow Earnings Coming This Week

Big Pharma Short Sellers Focus on a Couple of Favorites

9 Dividends That Should Absolutely Not Be Killed During the Coronavirus Recession

Short Sellers Run for Cover From Big Pharma Stocks

Big Pharma Scares Off Short Sellers

15 Top ESG Stocks That Look Undervalued for 2020

Big Pharma Sees a Rising Tide in Short Interest

Top Analyst Upgrades and Downgrades: AbbVie, Biogen, Boeing, Etsy, Gilead, GoPro, Micron, Newmont, Peloton, Pfizer, Valero, Zynga and More

Merck’s Spin-Off May Create Operational Risks for the Year Ahead

Is Merck Stuck in the Slow Lane?

The Case for Holding AVUV in Your Roth IRA

The Real Risk in Retirement Isn’t Running Out of Money. It’s Losing Your Purchasing Power.

He Thought Social Security Would Be Enough. A Knee Surgery and the Rising Cost of Living Sent Him Back to Work at 72.

The Real Risk in Retirement Isn't Running Out of Money. It's Losing Your Purchasing Power.

He Thought Social Security Would Be Enough. A Knee Surgery and the Rising Cost of Living Sent Him Back to Work at 72.

The Case for Holding AVUV in Your Roth IRA

The Real Risk in Retirement Isn’t Running Out of Money. It’s Losing Your Purchasing Power.

Merck : MRK

All Merck Articles

Apple, Boeing, Exxon, McDonald’s, Visa and More Dow Earnings This Week

Meet Merck’s Newest Collaborations in the Fight Against COVID-19

Why Pfizer and Merck Earnings Are Slowing the Dow

What to Watch When Merck and Pfizer Report Tuesday Morning

Big Pharma Short Sellers Can’t Make Up Their Minds

Apple, Exxon, Microsoft, Pfizer and More Dow Earnings Coming This Week

Big Pharma Short Sellers Focus on a Couple of Favorites

9 Dividends That Should Absolutely Not Be Killed During the Coronavirus Recession

Short Sellers Run for Cover From Big Pharma Stocks

Big Pharma Scares Off Short Sellers

15 Top ESG Stocks That Look Undervalued for 2020

Big Pharma Sees a Rising Tide in Short Interest

Top Analyst Upgrades and Downgrades: AbbVie, Biogen, Boeing, Etsy, Gilead, GoPro, Micron, Newmont, Peloton, Pfizer, Valero, Zynga and More

Merck’s Spin-Off May Create Operational Risks for the Year Ahead

Is Merck Stuck in the Slow Lane?

The Case for Holding AVUV in Your Roth IRA

The Real Risk in Retirement Isn’t Running Out of Money. It’s Losing Your Purchasing Power.

He Thought Social Security Would Be Enough. A Knee Surgery and the Rising Cost of Living Sent Him Back to Work at 72.

Featured Reads

The Real Risk in Retirement Isn't Running Out of Money. It's Losing Your Purchasing Power.

He Thought Social Security Would Be Enough. A Knee Surgery and the Rising Cost of Living Sent Him Back to Work at 72.